Impact of Systemic EGFR Inhibitors on Meibomian Glands: A Meibographic Analysis With Clinical Correlations
Systemic EGFR-I therapy may contribute to progressive MG loss, which may be associated with ocular side effects commonly observed in patients receiving these agents, including dry eye disease, blepharitis, and meibomitis. Early recognition and management of these complications by ophthalmologists may improve patient comfort and support adherence to oncologic treatment.
Authors
- Ferhan Guler
- Zarife Nurbanu Mendi
- Nilay Yuksel
- Edanur Onat
- Gokhan Ucar
Institutions
- University of Health Science (KH)
- Memorial Ankara Hospital (TR)
- Başkent University Hospital (TR)
- Sağlık Bilimleri Üniversitesi (TR)
- Ankara Yıldırım Beyazıt University (TR)
Publication Details
- Journal
- Cornea
- Published
- 2026-01-14
- DOI
- https://doi.org/10.1097/ico.0000000000004095
- Primary Topic
- Ocular Surface and Contact Lens
- Type
- article
- Field-Weighted Citation Impact
- 0.00